News - Onyx Pharmaceuticals, carfilzomib


Popular Filters

US and European hema-oncologists views therapies for relapsed/refractory multiple myeloma


US and European hematological oncologists surveyed by health care advisory firm Decision Resources indicate…

carfilzomibEuropeKyprolisMarkets & MarketingNorth AmericaOncologyOno PharmaceuticalOnyx PharmaceuticalsPharmaceuticalpomalidomide

Batch of mixed opinions from FDA advisory panels


Advisory panels of the US Food and Drug Administration meeting yesterday came back with a mixture of…

carfilzomibKyprolisMerck & CoNorth AmericaOncologyOnyx PharmaceuticalsPfizerPharmaceuticalPneumovaxPrevnarRegulationSanofisemuloparinVaccines

Onyx Pharma links with Texas MD Anderson Cancer Center on research


US biotech firm Onyx Pharmaceuticals (Nasdaq: ONXX) and The University of Texas MD Anderson Cancer Center…

BiotechnologycarfilzomibOncologyOnyx PharmaceuticalsoprozomibResearch

Onyx falls as FDA says no priority review for cancer drug


US drugmaker Onyx Pharmaceuticals (Nasdaq: ONXX) saw its shares fall 7.1% to $37.76 in early trading…

carfilzomibNorth AmericaOncologyOnyx PharmaceuticalsPharmaceuticalRegulation

Onyx Pharma files NDA for multiple myeloma drug carfilzomib


California, USA-based Onyx Pharmaceuticals (Nasdaq: ONXX) says it has completed the New Drug Application…

carfilzomibNorth AmericaOncologyOnyx PharmaceuticalsPharmaceuticalRegulation

Back to top